Your browser doesn't support javascript.
loading
Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer.
Jong, Kelly Xue Jing; Mohamed, Elsa Haniffah Mejia; Ibrahim, Zaridatul Aini.
Afiliación
  • Jong KXJ; Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
  • Mohamed EHM; Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
  • Ibrahim ZA; Department of Pharmacology, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. zaridatulaini@ummc.edu.my.
Apoptosis ; 27(11-12): 787-799, 2022 12.
Article en En | MEDLINE | ID: mdl-36207556
The development of targeted therapy such as tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-based therapy has gained increasing attention as a promising new approach in cancer therapy. TRAIL specifically targets cancer cells while sparing the normal cells, thus, limiting the known side effects of the majority anti-cancer therapies. As more extensive research and clinical trials are conducted, resistance to TRAIL molecule has become one of the significant issues associated with the failure of TRAIL in treating colorectal cancer (CRC). To date, the exact mechanism by which TRAIL resistance may have occurred remains unknown. Interestingly, recent studies have revealed the critical role of the TRAIL decoy receptor family; consisting of decoy receptor 1 (DcR1; also known as TRAIL-R3), decoy receptor 2 (DcR2; also known as TRAIL-R4), and osteoprotegerin (OPG) in driving TRAIL resistance. This review highlights the expression of the decoy receptors in CRC and its possible association with the reduction in sensitivity towards TRAIL treatment based on the currently available in vitro, in vivo, and human studies. Additionally, discrepancies between the outcomes from different research groups are discussed, and essential areas are highlighted for future investigation of the roles of decoy receptors in modulating TRAIL-induced apoptosis. Overcoming TRAIL resistance through modulating the expression(s) and elucidating the role(s) of TRAIL decoy receptors hold great promise for TRAIL-based therapies to be extensively explored in treating human cancers including CRC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Receptores del Ligando Inductor de Apoptosis Relacionado con TNF Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Apoptosis Año: 2022 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Receptores del Ligando Inductor de Apoptosis Relacionado con TNF Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Apoptosis Año: 2022 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: Países Bajos